Biotech Values

[mcbio]

Re: CYPB

Data from phase IIb trial showed improved cognitive function #msg-41779373 and I assume this is how CYPB would try to distinct this drug from other antipsychotic drugs in the schizophrenia market but the regulatory path is not clear from here - will the drug proceed straight to phase III or will another phase IIb be required and how big the trial/s will be. So, there's a reasonable chance CYPB will need a big pharma partner in order to bring this drug to the market.

It appeared from the PR that the improved cognitive function would be the angle that CYPB would try to focus on as it pushes forward with this drug's development whether alone or with a big pharma partner. My other big question is how truly novel of a drug is CYP-1020? The PR references the drug's GABA enhancement that may provide the basis for improved cognition relative to other schizophrenia drugs. But, isn't GABA a well-known target? I would assume other schizophrenia drugs in the past have targeted GABA to some extent. Is CYP-1020 truly a novel drug?